Papers/PMID:36790138
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.
The Cochrane database of systematic reviews2023The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
myo-inositol — decreases preterm birth incidence
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“However, myo-inositol may be associated with a reduction in the incidence of preterm birth (RR 0.35, 95% CI 0.17 to 0.70; 4 studies; 829 infants).”
Quoted verbatim from Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.. - Study
- meta-analysis
- Participants
- 829
- Population
- Pregnant women 10 to 24 weeks pregnant at the start of the trials, pooled across four randomised trials (829 infants)
Effect 0.35 risk ratio, 95% CI 0.17 to 0.7
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.2023PMID:36790138Permalink